FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma
On March 20, 2026, the Food and Drug Administration approved nivolumab with doxorubicin, vinblastine, and…
Browsing: FDA Approvals
FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation
On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi,…
FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukeamia or small lymphocytic lymphoma
On February 19, 2026, the Food and Drug Administration approved acalabrutinib tablets and capsules in…
FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
The Food and Drug Administration (FDA) has approved pembrolizumab as well as pembrolizumab and berahyaluronidase…
FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma
On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel for adults with relapsed…
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer
On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate with prednisone…
FDA approves epcoritamab-bysp for follicular lymphoma indications
On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp with lenalidomide and rituximab for…
AI-driven study reports identifying (Z)-endoxifen as a potential therapeutic candidate for glioblastoma
On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle for…
FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer
On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle for…
FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas
On November 19, 2025, the Food and Drug Administration approved selumetinib for adults with neurofibromatosis…